Kaya Ltd. moves to reshape its capital structure

The issue price is Rs 274.10 per equity share for the preferential allotment of 18,24,150 shares. ^[1]

Using the latest pre-allotment equity share capital of Rs 15.19 Crores ^[2] and the Rs 10 face value per share ^[1]:

• Existing shares: 1,51,90,000
• New shares issued: 18,24,150
• Post-allotment shares: 1,70,14,150
• Post-allotment dilution to existing shareholders: 10.72%

The new issue represents 12.01% of the pre-issue share base; equivalently, existing shareholders’ ownership falls to approximately 89.28% post-allotment.

The preferential issue is primarily a growth and liquidity funding exercise, not a specified debt-refinancing transaction. Kaya plans to deploy the Rs 50.00 Crores gross proceeds by FY28 as follows: 50% for clinic expansion and equipment, 25% for working capital, and 25% for general corporate purposes. ^[3]

Balance-sheet relevance

As of Q1 FY27, Kaya reported total debt of Rs 163.21 Crores and net debt of Rs 161.82 Crores, with cash and equivalents of only Rs 1.39 Crores. ^{[5] [6] [7]} The company also had negative total equity of Rs 152.76 Crores. ^[8] The limited-review disclosure described the company as having a negative working-capital position, while stating that management expected financing arrangements and operating cash generation to support working capital and capex. ^[9]

• Direct debt reduction: No portion of the issue is explicitly earmarked for repayment of borrowings. Therefore, the issue cannot be treated as a committed debt paydown.
• Potential debt capacity: If the entire Rs 12.50 Crores allocated to general corporate purposes were applied to debt, it would cover approximately 7.66% of total debt, calculated as Rs 12.50 Crores divided by Rs 163.21 Crores. If the working-capital allocation were also diverted to debt, the combined Rs 25.00 Crores would cover approximately 15.32% of total debt. These are hypothetical applications, not the stated funding plan.
• Net-debt perspective: The full Rs 50.00 Crores issue proceeds equal approximately 30.90% of reported net debt, but the stated uses do not direct the full amount toward deleveraging. The calculation uses Rs 50.00 Crores divided by Rs 161.82 Crores. ^{[6] [4]}
• Working capital: The earmarked Rs 12.50 Crores directly addresses part of the working-capital requirement, particularly inventory and vendor payments. However, the company has not quantified the negative working-capital deficit in the cited disclosure, so the percentage of the requirement covered cannot be determined. ^{[3] [9]}

Implication: the capital infusion should strengthen near-term liquidity and support operating expansion, but it does not materially de-risk the balance sheet through a defined debt repayment programme. Its effectiveness will depend on whether the clinic capex generates cash returns, whether the Rs 12.50 Crores working-capital tranche is sufficient, and whether general corporate funds are ultimately used for operations, interest obligations, or borrowings. The latest quarterly disclosure does not provide a lender-wise debt schedule, maturity profile, or quantified working-capital gap against which coverage can be measured.

No promoter-group participation is identified in the filing. The proposed allottees are Axana Estates LLP and Plutus Investments India Private Limited; the disclosure does not describe either entity as belonging to the promoter or promoter group. Therefore, the precise conclusion is that promoter participation is not disclosed, rather than that it is definitively absent. ^[1]

• Issue price: Rs 274.10 per equity share, for 18,24,150 shares; total issue size is approximately Rs 50.00 Crores. ^[1]
• Book value comparison: The latest reported consolidated book value per share is negative Rs 10.06 for Q1 FY27. ^[10] Accordingly, the issue price is Rs 284.16 above the reported book value per share, on a direct arithmetic basis. Since book value is negative, a conventional price-to-book comparison is not meaningful.
• Recent trading averages: The regulatory-filing extract does not provide the recent trading averages or the benchmark VWAP figures against which the issue price was determined. The issue price therefore cannot be quantitatively compared with those averages from the cited disclosure.